From: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
System organ class/preferred term | Placebo (n = 182) | Aclidinium 200 μg (n = 183) | Aclidinium 400 μg (n = 177) |
---|---|---|---|
Cardiac disorders | |||
Tachycardia | 0 | 0 | 1 (0.6) |
Arrhythmia | 1 (0.5) | 0 | 0 |
Bradycardia | 2 (1.1) | 0 | 0 |
Palpitations | 0 | 2 (1.1) | 0 |
Increased heart ratea | 0 | 2 (1.1) | 0 |
Eye disorders | |||
Transient blindness | 0 | 1 (0.5) | 0 |
Reduced visual acuity | 0 | 1 (0.5) | 0 |
Gastrointestinal disorders | |||
Constipation | 3 (1.6) | 1 (0.5) | 0 |
Dry mouth | 1 (0.5) | 2 (1.1) | 3 (1.7) |
Infections and infestation disorders | |||
Urinary tract infection | 0 | 3 (1.6) | 1 (0.6) |
Nervous system disorders | |||
Optic neuritis | 0 | 0 | 1 (0.6) |
Renal and urinary disorders | |||
Urinary retention | 0 | 0 | 1 (0.6) |
Urinary incontinence | 1 (0.5) | 0 | 0 |